What is Acurion?
Acurion is a San Diego-based company focused on advancing precision medicine through its AI-powered OncoGaze platform. This innovative technology extracts clinically actionable insights and biomarker information directly from conventional pathology images, a process that bypasses the need for additional tissue samples or specialized molecular testing. By leveraging routine pathology slides prepared during standard clinical care, Acurion offers a scalable and accessible approach to biomarker detection, aiming to address critical delays and access issues in precision oncology. The company's technology is designed to improve treatment selection across various advanced cancer types, enhancing the application of targeted therapies.
How much funding has Acurion raised?
Acurion has raised a total of $4.3M across 1 funding round:
Seed
$4.3M
Seed (2026): $4.3M with participation from National Foundation for Cancer Research, Mesa Verde, and Asian Fund for Cancer Research
Key Investors in Acurion
National Foundation for Cancer Research
The National Foundation for Cancer Research is a nonprofit organization dedicated to funding innovative cancer research aimed at finding cures for all types of cancer. They provide essential financial support to scientists working on groundbreaking discoveries in cancer treatment, detection, and prevention.
Mesa Verde
Mesa Verde Venture Partners is an early-stage life sciences venture capital firm based in San Diego, CA, dedicated to partnering with entrepreneurs to build successful companies. They target areas such as pharmaceuticals, medical devices, diagnostics, life science enabling tools, and digital health.
Asian Fund for Cancer Research
The Asian Fund for Cancer Research Limited (AFCR) is dedicated to funding cancer research, particularly focusing on cancers prevalent in Asian populations. They support innovative research projects aimed at understanding cancer formation, spread, and treatment.
What's next for Acurion?
With the recent major strategic investment, Acurion is poised to accelerate its development and market penetration. The substantial capital infusion, particularly in the context of a major enterprise-level funding, suggests the company is moving beyond its early stages and is likely focused on scaling its operations, expanding its research and development capabilities, and potentially forging strategic partnerships. This financing will be instrumental in further validating the OncoGaze platform and broadening its impact on patient care by improving access to essential biomarker information for treatment decisions.
See full Acurion company page
